This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $178.19, marking a +0.87% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy
by Zacks Equity Research
Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy are included in this Analyst Blog.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Earnings Outlook for 2023 and Featured Reports for Apple, JNJ, & Others
by Sheraz Mian
Today's Research Daily an earnings update and features new research reports on Apple (AAPL), JNJ (JNJ), CSX (CSX) & Others.
Johnson & Johnson (JNJ) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $176.66 in the latest trading session, marking a -0.43% move from the prior day.
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Johnson & Johnson (JNJ) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $175.48, marking a -0.11% move from the previous day.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
by Zacks Equity Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
by Zacks Equity Research
Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.
4 Large Drug Stocks to Watch in a Booming Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $177.84, moving +1.19% from the previous trading session.
The Return of "Merger Monday"
by Andrew Rocco
Two major deals in the biotech and software industry were inked this weekend.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ETF Investing Strategies for 2023
by Neena Mishra
We discuss the market outlook and investing strategies for 2023.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $176.10, moving -1.5% from the previous trading session.